Daniela V. Castro

CRA @CityofHope | Aspiring Physician | Interested in GU Oncology | MS @UCSanDiego | #HealthEquity | #TeamPal | Tweets are my own.

[George Zhang @ActuallyGZhang]

First ever #ASCOGU, and I feel so excited to have presented our analysis of RCC clinical trial availability in the U.S. As the treatment landscape advances, which populations are being represented? So much love to all of #TeamPal @cityofhope for their support ❤️ @ASCO #GU26

[koral shah, md @kor_shah]

Kicking off #SoCalGU26 with this incredible RCC panel highlighting active trials open across Southern California!
@montypal @siadaneshmand @YuWeiChenMD @KidneyCancerDoc @WesleyYipMD, Nataliya Mar, & Hyung Kim

@MOASC_Office

[Miguel Zugman, MD @mzugman]

Thank you for the highlight, my friend!

Please don’t miss a great session, covering many other biomarkers, including LAG3 and KIM-1 in ccRCC and PD-L1 expression in the context of the SUNNIFORECAST trial.

@DrRanaMcKay @VincentWenxinXu @TiansterZhang

[Hedyeh Ebrahimi @EbrahimiHedyeh]

⏰Happening now!

Great line-up ahead in Hall 7.1c at #ESMO25

“Optimising management of localised bladder cancer” moderated by @ReginaBarCar & @karima_oualla

@OncoAlert @OncLive

[Hedyeh Ebrahimi @EbrahimiHedyeh]

Great overview by @_ShankarSiva at #ESMO25 on the role of SABR/SBRT in oligoprogressive RCC

SABR is safe, non-invasive, and allows continuation of systemic therapy without interruption

Ongoing trials are actively exploring its synergy with systemic therapy

@urotoday @OncoAlert @yunroseli

[Sumanta K. Pal, MD, FASCO @montypal]

What a pleasure to work with @vabreugoes - a terrific scholar from @hosp_einstein. Impressive presentation at #ASCOQLTY25 - & so glad he connected w @PauloBergerot & @crisbergerot @oncoclinicas (fmr @cityofhope) as well!

[Salvador Jaime-Casas, MD @SalvadorjcMD]

🚨 Thrilled to share our new manuscript in @Cancers_MDPI! 🚀 We evaluated clinical & pathologic predictors for pUS at cystectomy in pts with MIBC.

Huge thanks to the team at @cityofhope @CityofHope_GU and to incredible mentors @AbhiTrip87 @montypal @WesleyYipMD @ClaytonLauMD 🙏

👥 Pts cT2-4N0M0 grouped: 1️⃣ pUS w/o NAC 2️⃣ pUS w/ NAC 3️⃣ No pUS
📊 277 pts; 38.6% (n=107) had pUS, 37 w/ NAC and 70 w/o NAC
💧 Preop hydronephrosis = higher odds of pUS [OR 2.24]
⬇️ pUS (w/ or w/o NAC) = worse OS & RFS vs no pUS
🏆 Strongest predictor for pUS at: Preop hydronephrosis

🔎 Takeaway: Need better pre-op risk assessment in MIBC! ⚠️ High-risk features like hydronephrosis should prompt closer evaluation due to pUS risk at cystectomy.

https://t.co/TjvfSzxEiX

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

Excited to share our new paper @EurUrolOncol! 🎉 We developed patient-centered, stage-specific FKSI-23 tools to better capture HRQOL in localized & metastatic RCC, moving beyond generic instruments to what truly matters to patients @tompowles1 @montypal

https://t.co/2sTCZRdIjH

[Salvador Jaime-Casas, MD @SalvadorjcMD]

1/ JUST PUBLISHED at #CGC journal: Evaluating Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical Cystectomy

🔵Occult LN involvement occurs in 25% of pts with cN0 MIBC.
🔵LN involvement can significantly affect oncologic outcomes, with 5-yr OS rate of approx 32%, compared to 75% in pts without LN involvement.
🔵We leveraged our institutional database to determine clinical and pathological variables associated with pLN+ in patients with clinically node-negative BC (cN0)

https://t.co/kCfFKhrNim

[Sumanta K. Pal, MD, FASCO @montypal]

Terrific conference that so many of my @cityofhope colleagues have benefitted from - @NazliDizman @AlexisLevee @DVCastro_ @ReginaBarCar @EbrahimiHedyeh - please consider attending!

[Nick Salgia @NickSalgia]

Excited to share the bulk of my thesis work available online today @CancerCell. We sought to dive into the tumor microenvironment of sarcomatoid renal cell carcinomas to better understand what makes RCC tumors susceptible to immunotherapy: https://t.co/HtWABXjj7h
1/n

[Sumanta K. Pal, MD, FASCO @montypal]

Proud of @ruchia_upenn, a @Penn undergraduate who spent her summers working with us at @cityofhope. Today she presented her work with @ReginaBarCar @incanMX on international #kidneycancer trial availability - so impressive!

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

Huge congrats to @JasnoorMalhotra and #ASchlager on this important paper @EurUrolFocus reviewing HRQOL assessments in mRCC clinical trials!
A timely synthesis of the strengths & gaps in current PROMs; a clear call for more patient-centered tools 👏

https://t.co/Tj7ElYlUFG

[Hedyeh Ebrahimi @EbrahimiHedyeh]

🥗 Powerful diet-focused study at #ASCO25 presented by @SaraKCharMD from CALGB/SWOG 80702:

🔹 Proinflammatory diet linked to worse OS in stage III colon cancer
🔹 Best outcomes in patients with high physical activity and anti-inflammatory diet
🔹 NSAIDs didn’t alter the diet-survival link

🙌 Love seeing nutrition, microbiome, & exercise take the podium spotlight @ASCO!
@OncoAlert

[Sumanta K. Pal, MD, FASCO @montypal]

Huge congrats to @NazliDizman @MDAndersonNews! Can affirm that all the below is true! So proud. #ASCO25

[Hedyeh Ebrahimi @EbrahimiHedyeh]

🏔️ A standing ovation at #ASCO25 for Dr. Christopher Booth and the CHALLENGE (CO.21) trial.

A 3-year structured exercise program post-chemo in stage II/III colon cancer:
✅ Improved OS (HR 0.63, p=0.022)
✅ 1 life saved for every 14 patients

💬 “Exercise is no longer just a QOL intervention - it is a treatment for colon cancer.”

📖 Simultaneously published in @NEJM today.
#ColorectalCancer @CDNCancerTrials @ASCO @OncoAlert

[Sumanta K. Pal, MD, FASCO @montypal]

What a wonderful moment - seeing @AlexisLevee get ready to take the stage to claim her @ASCO Young Investigator Award! So proud of all her tremendous accomplishments as a fellow at @cityofhope (she got an excellent foundation from @hmcarthur in residency - her co-mentor on this grant!). Excited for her next stage as a #breastcancer-focused investigator at @UCLAHealth w @dradityabardia.

[Zeynep Zengin @ZeynepZengin]

#AACR25

In our study high baseline CD5 B cells linked to worse outcomes in mRCC patients treated with cabo/nivo.

➡️CD5+ B cells may be a prognostic biomarker—and potential target—for ICB response

Thank you @montypal @kortylmt @EbrahimiHedyeh and @AlcantaraMarice!

[Zeynep Zengin @ZeynepZengin]

It’s been a minute!
Good morning Chicago ☀️

I will be at @AACR today presenting our work on CD5 cells and IO response. If you are interested in learning more, join me at Section 32/Board 26 (9-12AM PST).

Appreciate the support of @montypal who made this possible and @kortylmt

[Salvador Jaime-Casas, MD @SalvadorjcMD]

Incredible paper led by @DVCastro_ exploring the impact of insurance status on oncologic outcomes in pts with mRCC. @JCO_ASCO #OncologyAdvances